GlassScriptPhysician profile
Christos Bovetas
NPI 1487740262
$7,820.89
in general payments reported to CMS, 2019-2025
41 companies · $1,116 in 2025
The $1,116 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $827 · 2020: $1,017 · 2021: $1,307 · 2022: $1,072 · 2023: $1,114 · 2024: $1,368 · 2025: $1,116.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,598.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,597.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,924.92 | 2019-2025 | Repatha, Otezla, Otezla |
| Astrazeneca Pharmaceuticals LP | $1,062.87 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $729.84 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $676.03 | 2019-2025 | Ubrelvy, Linzess, Qulipta |
| Merck Sharp & Dohme LLC | $326.17 | 2019-2022 | |
| Glaxosmithkline, LLC. | $294.03 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $262.01 | 2020-2024 | Jardiance, Spiriva Respimat |
| Lilly USA, LLC | $261.01 | 2020-2025 | Mounjaro, Zepbound, Emgality |
| Novartis Pharmaceuticals Corporation | $258.43 | 2019-2025 | |
| Biohaven Pharmaceuticals, INC. | $239.46 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $210.50 | 2019-2025 | Xifaxan |
| Pfizer INC. | $152.80 | 2019-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $146.89 | 2022 | |
| Astellas Pharma US INC | $105.38 | 2019-2024 | Veozah, Myrbetriq |
| Almatica Pharma LLC | $94.58 | 2024 | Loreev Xr, Teriparatide |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $93.91 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $80.41 | 2020-2022 | |
| Abbott Laboratories | $78.98 | 2022-2025 | Freestyle Libre 3 |
| E.R. Squibb & Sons, L.L.C. | $75.83 | 2020-2025 | Camzyos |
| Allergan, INC. | $72.59 | 2019-2020 | |
| Cvrx, INC. | $58.01 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $57.89 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $54.46 | 2022-2023 | Trintellix |
| Mylan Specialty L.P. | $49.81 | 2019-2023 | Yupelri |
| Xeris Pharmaceuticals, INC. | $44.70 | 2022-2025 | Recorlev |
| Dexcom, INC. | $43.53 | 2019-2025 | Dexcom G6 Transmitter |
| Esperion Therapeutics, INC. | $40.52 | 2021-2024 | Nexletol |
| Bausch Health US, LLC | $39.16 | 2020-2022 | |
| Smith+Nephew, INC. | $37.93 | 2023 | Grafix |
| Dermira, INC. | $27.88 | 2020 | |
| Si-Bone, INC. | $26.67 | 2020 | |
| Amarin Pharma, INC. | $23.75 | 2019 | |
| Mannkind Corporation | $23.47 | 2021 | |
| Medtronic, INC. | $22.37 | 2023 | Mazor X System |
| Hologic Sales and Service, LLC | $21.62 | 2024 | Aptima, Thinprep 2000 Processor |
| Sunovion Pharmaceuticals INC. | $19.87 | 2020 | |
| Edwards Lifesciences Corporation | $19.04 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Arbor Pharmaceuticals, INC. | $18.57 | 2021 | |
| Antares Pharma, INC. | $17.37 | 2023 | Xyosted, Tlando, Nocdurna |
| Tolmar, INC. | $14.61 | 2023 | |
| Sanofi Pasteur INC. | $13.02 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christos Bovetas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.